Navigation Links
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Date:11/15/2011

AMSTERDAM, November 16, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan designation in the European Union provides several benefits including 10 years of market exclusivity from product launch and access to the central authorization procedure.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"Orphan designation is an important milestone for our hemophilia B gene therapy program and will provide additional support to our negotiations as we seek potential licensing partners," said Jörn Aldag, CEO of AMT. "A successful gene therapy for hemophilia could dramatically change not only the lives of patients but also the current hemophilia market that is dominated by protein replacement therapies."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to desi
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
2. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
3. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
6. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
7. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ALBANY, New York , September 2, 2014 ... market report published by Transparency Market Research "Latin ... and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility ... Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and ... Share, Growth, Trends and Forecast, 2014 - 2020" ...
(Date:9/2/2014)... 2, 2014 According to the ... Pre-packed, Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... Forecast to 2018", published by MarketsandMarkets, the Chiral Chromatography ... is poised to grow at a CAGR of 5.2% ... Browse 90 market data tables and 15 ...
(Date:9/2/2014)... 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the Morgan Stanley Global Healthcare Conference ... Presentation date: Tuesday September 9, 2014 , Presentation time: ... and 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... WASHINGTON, Nov. 16, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).  The use of these ...
... Inc. (NYSE Amex: PIP ) announced today that ... bioscavenger programs will be presented at the 2011 Chemical and ... in Las Vegas, NV, November 14-18, 2011. "The ... industry meetings and it is an honor to present among ...
Cached Medicine Technology:Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $1.1 Billion in Michigan 2PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference 2PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference 3
(Date:9/3/2014)... CS3 Technology, a Sage North America ... of Sage 100 ERP, Sage 500 ERP, and Sage ... Dollar Club achiever for surpassing a million dollars in ... Technology and all Million Dollar Club achievers for the ... its business partners and the mutual customers they serve. ...
(Date:9/3/2014)... Job seekers who are interested in expanding their ... do both on iHire. By incorporating MOOCtracks into the ... investigating employment and educational opportunities in the same place. ... skills gaps and challenging the landscape of education by ... and mortar universities. To make it easier for their ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 IMCA Speedway ... kick off on September 1, 2014 at the IMCA ... the pre-race ceremony will include a check presentation to ... The Warriors® is a national nonprofit organization that assists ... fallen who have sustained physical and psychological wounds in ...
(Date:9/2/2014)... 2014 Scientists, physicians, patients, families, ... Bay from September 4-6 for the Friedreich’s Ataxia ... FARA Energy Ball Gala. The Energy Ball ... in their pursuit of treatment and cure for ... neuromuscular disease Friedreich’s ataxia (FA). , “The annual ...
(Date:9/2/2014)... Illinois (PRWEB) September 02, 2014 ... Chief Executive Officer and Chief Information Officer Strategy ... Carlton Chicago. , Becker's Hospital Review Chief Executive ... together hospital and health system Chief Executive Officers, ... hospital and health system executives through high-quality ...
Breaking Medicine News(10 mins):Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:iHire Announces Partnership with MOOCtracks 2Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4
... during Long-Term Care Awareness Week, WASHINGTON, Nov. ... they have coverage for long-term care expenses,according to ... Insurance,Plans (AHIP). The survey found that many Baby ... services and have not thought about,long-term care insurance. ...
... -- Recovery from heart attacks is best served by ... of patients who have had a heart attack stop ... results from a Mayo Clinic study presented today at ... Fla. , The Mayo data also show that in ...
... such fare more likely to act out at 7, 10, ... boys exposed to violent television -- even cartoons -- are ... , Their findings don,t definitively prove that TV makes children ... according to the researchers. But the link does appear solid ...
... single author. With research being conducted by teams of scientists, ... to a new study led by a scientist at the ... from evenly distributed, and the order in which the authors ... findings appear in the Nov. 1 issue of the scientific ...
... Prescribe Exercise to Patients, WASHINGTON, Nov. 5 ... the American Medical Association (AMA) today,launched Exercise is ... to incorporate physical activity and exercise into their,daily ... prescribe,exercise to their patients., A recent survey ...
... Therapeutics, Inc.,(Nasdaq: CVTX ) announced today that ... the primary composite endpoint of CV,death, myocardial infarction ... in 1,935 patients with an elevated (>80pg/ml) level ... study (p=0.009). The data were presented today ...
Cached Medicine News:Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:Mayo Clinic study finds that after heart attack most patients stop taking life-saving drugs 2Health News:TV Violence May Spur Aggression in Boys 2Health News:TV Violence May Spur Aggression in Boys 3Health News:Lost in the middle: author order matters, new paper says 2Health News:ACSM and AMA Launch 'Exercise Is Medicine' Program 2Health News:ACSM and AMA Launch 'Exercise Is Medicine' Program 3Health News:Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP 2Health News:Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP 3
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The Retina 145 L direct contact glass is a panfundus wide-angle viewing device designed to facilitate the problem-free diagnosis and treatment of the retina as far as the equator....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
Medicine Products: